Clinical Trial Update: Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating neoadjuvant durvalumab (MEDI4736) followed by radical radiotherapy or chemoradiotherapy in non-surgical early stage or locally adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Instituto Portugues de Oncologia, Francisco Gentil, Porto | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN